Gynostemma pentaphyllum (Jiaogulan)

TL;DR — Gynostemma pentaphyllum ("Jiaogulan," the Southern Chinese "herb of immortality") contains gypenosides — dammarane-type saponins structurally related to ginsenosides — that, once heat-processed into damulins A and B, directly activate AMPK. Three small human RCTs, all at the same 450 mg/day dose, report real body-composition, lipid, and exercise-performance effects. The catch: all three are funded by the extract's manufacturer, none is independently replicated at scale, and the AMPKAn energy-sensing enzyme activated when ATP is low — it promotes fat burning, mitochondrial biogenesis, and autophagy. Full glossary → story — while mechanistically real — has not been tested against a hard longevity endpoint. Tier C: a legitimate, cheap AMPK-activator candidate, not a settled metabolic intervention.

01What Gynostemma pentaphyllum (Jiaogulan) does (and why it matters)

Gynostemma pentaphyllum is a climbing vine in the Cucurbitaceae family, used for centuries in Chinese folk medicine and now studied primarily for one property: its gypenosides — more than 80 dammarane-type saponins that share a biosynthetic backbone with Panax ginseng's ginsenosides, which is why the plant is sometimes marketed as "Southern ginseng." Raw gypenosides are only weakly active. What changed the research picture was heat processing: autoclaving the extract hydrolyzes native gypenosides into two specific compounds, damulin A and damulin B, which are the fraction actually shown to activate AMPK in cell and animal models. This distinction — processed vs. raw extract — is not marketing trivia; it is the mechanistic hinge the human trials below depend on.

Traditional use of Gynostemma leans adaptogenic — fatigue, stress resilience, general "tonic" claims — and there is a separate small literature on gypenoside-containing extracts for fatigue and anxiety symptoms. TNiC deliberately does not lean on that literature here: those trials measure subjective symptom scales in different populations and don't bear on the AMPK/metabolic mechanism this page is built around. What follows is scoped to the metabolic and mitochondrial evidence — the part of the Gynostemma story with a real, repeated dose-response signal.

Primary hallmarks targeted: Deregulated nutrient sensing · Mitochondrial dysfunction

02Mechanism — a different route to AMPK than berberine's

Where berberine reaches AMPK indirectly — inhibiting mitochondrial Complex I to create an energy-deficit signal the cell then responds to — the damulin fraction of processed Gynostemma appears to engage AMPK more directly in myotube and animal models. Both compounds land on the same downstream kinase, which is the mechanistic basis for calling Gynostemma a "cheap berberine-adjacent" AMPK activator, but the human evidence behind that claim is far thinner: one head-to-head RCT anchors berberine against metformin, while Gynostemma has three small placebo-controlled trials and no active comparator.

03Evidence summary

Consensus: Tier C. What's genuinely notable is the consistency: three independent human trials converge on the same 450 mg/day dose and report directionally aligned body-composition, lipid, and metabolic effects — unusually tight replication for a botanical. What holds this back from Tier B: every human trial to date is funded by the ingredient's commercial manufacturer, none has been independently replicated by an unaffiliated group, sample sizes are modest (16–117), and the dyslipidemia systematic review pools mostly Chinese-language trials of uneven blinding quality. No trial measures a hard longevity or hallmark-level endpoint — this is early, promising metabolic-marker evidence, not a settled intervention.

04Dosing protocol

05Monitoring

06Safety, red flags, and contraindications

• Generally well tolerated in trials — none of the three human RCTs reported serious adverse events at 450 mg/day over 4–16 weeks; the systematic review likewise found fewer adverse events than lipid-lowering drugs across the pooled 22 RCTs.
• Mild GI upset is the most commonly reported effect for saponin-containing botanicals generally — take with food if it occurs.
• Theoretical additive hypoglycemia risk — because damulins and berberine/metformin converge on the same AMPK/ACC axis, stacking them is a plausible but untested interaction.

What would change this grade. Gynostemma is C — consistent but sponsor-funded metabolic-marker trials. Independent replication by an unaffiliated group, or a trial with a hard endpoint, would move it toward B; until then the funding and surrogate endpoints keep it capped.

07Synergies and antagonists

Pairs well with:

Works against / redundant with:

08Personal results template